---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-035735"
form_type: "8-K"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:14:15.388635+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Abpro/Celltrion ABP-102/CT-P72 preclinical data at AACR 2025 shows potential best-in-class HER2 x CD3 T-cell engager

## Summary
- ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.
- Up to 2-fold increase in tumor suppression vs. runimotamab biosimilar in HER2-overexpressing cancer models.
- Reduced cytokine release and tolerated >180x the MTD of parental antibody in monkeys, suggesting wider therapeutic window.
- Phase 1 clinical trials planned to commence in first half of 2026.

## SEC filing metadata
- accession: 0001213900-25-035735
- form_type: 8-K
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000121390025035735/0001213900-25-035735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000121390025035735/ea0239349-8k_abprohold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-035735
- JSON: https://secwatch.observer/filing/0001213900-25-035735.json
- Plain text: https://secwatch.observer/filing/0001213900-25-035735.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.